TITLE

Set up 'research insurer' to keep CT billings accurate and compliant

PUB. DATE
June 2008
SOURCE
Clinical Trials Administrator;Jun2008, Vol. 6 Issue 6, p67
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article suggests steps for hospital research centers in ensuring research billing accuracy and compliance with regulations. The hiring of frontline people to handle the billing processes is advised to ensure compliance. Having a financial analysis of the research protocol, as suggested, will likely result into less billing to the Medicare. A spreadsheet listing that include costs, Institutional Review Board submission and review, among others, is also recommended.
ACCESSION #
32138516

 

Related Articles

  • Sangart Completes $50M Series F for MP4 Molecule.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p5 

    The article reports that San Diego, California-based Sangart Inc. has already received the final $50 million out its Series F financing round which was initiated in 2007. The newly-added $50 million has made the company to have a total funding of about $100 million. The company shares that the...

  • Affymax $70M Offering Oversold Before Phase III.  // Bioworld Week;11/23/2009, Vol. 17 Issue 47, p5 

    The article reports on the status of biopharmaceutical firm Affymax Inc.'s finances for use in its four pivotal Phase III trails of Hematide in Palo Alto, California in 2010. It mentions that the company has enough cash and finances to further the research of the drug because it priced a 70...

  • The risk of bias from omitted research. Garattini, Silvio; Liberati, Alessandro // BMJ: British Medical Journal (International Edition);10/07/2000, Vol. 321 Issue 7265, p845 

    Editorial. Discusses the impact of bias caused by omitted research on the integrity of evidence-based health care in Europe. Efforts of medical organizations to correct the imbalances created by research omissions; Impact of economic interests on the effectiveness of medical care and research;...

  • MethylGene Pulls in $35M for Cancer, Antifungal Work.  // Bioworld Week;3/28/2011, Vol. 19 Issue 13, p1 

    The article reports on the disclosure of a 35.3 million U.S. dollars financing to boost the work of Montreal, Quebec-based MethylGene Inc.'s programs in cancer and fungal infections on March 24, 2011. It states that the net proceeds of the financing will be used to push its two lead programs...

  • Immatics Biotechnologies Secures $70.6M for IMA901. Moran, Nuala // BioWorld International;9/22/2010, Vol. 15 Issue 37, p1 

    The article offers information on a third private round of financing secured by Immatics Biotechnologies GmbH. The funding, valued at 53.8 million euros, will be used to finance a Phase III trial of its IMA901 in renal cell carcinoma treatment. The company's previous financing round in February...

  • Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons. Morrison, Trista // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p1 

    The article reports on the 30 million U.S. dollar Series B financing secured by Ophtotech Corp. The financing round is designed to support the clinical trials of the company's age-related macular degeneration (AMD) drugs. Samir Patel, president and chief executive officer (CEO) of Ophthotech,...

  • Financings Roundup.  // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p7 

    The article reports on the stock offering of Bio-Path Holdings Inc. The company was able to raise 650,000 U.S. dollars in its offering of shares of common stock and warrants. Proceeds from the stock offering will be used in funding the clinical trial of its lead product candidate. Bio-Path plans...

  • Clovis Oncology Files for $149.5M Initial Public Offering. Shaffer, Catherine // BioWorld Today;6/24/2011, Vol. 22 Issue 122, p1 

    The article reports on an initial public offering (IPO) issued by Clovis Oncology Inc. on June 23, 2011. With a value of up to 149.5 million U.S. dollars, the deal is considered the largest biotechnology IPO in 2011. The proceeds from the offering will be used to finance clinical trials of drugs...

  • GTx to Raise $47.5M to Develop Cancer Drugs. Serebrov, Mari // BioWorld Today;6/24/2011, Vol. 22 Issue 122, p1 

    The article reports on the plan of GTx Inc. to raise 47.5 million U.S. dollars on a public offering in order to finance Phase III development of Ostarine and Phase II trials for Capesaris. Expected to close on June 28, 2008, the offering entails the sale of 10 million shares at 4.75 U.S. dollars...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics